Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

Targeting angiogenesis in glioblastoma (GBM) may improve patient outcome by normalizing tumor vasculature and improving delivery of chemotherapeutics and oxygen. Consequently, concomitant administration of small molecule inhibitors of the VEGF pathway will likely have a positive impact on chemoradia...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gerstner, Elizabeth R., Eichler, April F., Plotkin, Scott R., Drappatz, Jan, Doyle, Colin L., Xu, Lei, Duda, Dan G., Wen, Patrick Y., Jain, Rakesh K., Batchelor, Tracy T.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4090923/
https://ncbi.nlm.nih.gov/pubmed/20821342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0390-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars